The markets are trading relatively flat ahead of the open today. G7 foreign ministers from industrialized nations are set to meet with Middle East stakeholders, and U.S. Secretary of State Rex Tillerson will be visiting Moscow today to meet Sergey Lavrov. That said, gold was trading higher during the pre-market, with gold futures for delivery in June 2017 trading around the $1,260 level. In her speech yesterday, Fed Reserve Chair Janet Yellen indicated the U.S. economy was healthy, and it’s focused on maintaining grow over the the next few years.
As a reminder, earnings season is about to kick off, with some banks reporting this Thursday. Moving on, there are some stocks moving during the pre-market, and here’s what we’re watching ahead of the open:
RetailMeNot Inc (NASDAQ:SALE)
Shares of RetailMeNot Inc (NASDAQ:SALE) are trading nearly 50% higher during the pre-market, after Harland Clarke, a marketing and payment services company, agreed to acquire RetailMeNot in a deal worth $630M in equity. Harland Clarke agreed to acquire all the shares of SALE’s Series 1 common stock for $11.60 per share, in cash. Here’s a look at SALE’s chart, as of the close on April 10, 2017:
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares were up over 40% in the premarket after it reported results from its U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting, which confirmed that the single-study NDA approval of TNX-102 SL may be possible, after topline data from its ongoing study suggested that it could be used for the treatment of PTSD. Now, in general, the FDA’s standard for drug approval requires two positive Phase III trials, but TNXP could possibly gain NDA approval with this single study. Here’s a look at TNXP’s chart, as of yesterday’s close:
Idera Pharmaceuticals Inc (NASDAQ:IDRA)
Idera Pharmaceuticals Inc (NASDAQ:IDRA) was trading over 10% higher ahead of the open, after it announced its intratumoral IMO-2125 successfully completed the Phase I portion of its ongoing Phase I/II clinical trial. Enrollment for the Phase II portion of the trial has already started, and patients in the trial will be given an 8mg dose of intratumoral IMO-2125. Additionally, the company is engaging in discussions with regulatory authorities, regarding the registration for IMO-2125 in combination with ipilimumab in PD-1 refractory metastatic melanoma patients. Here’s a look at IDRA’s chart, as of yesterday’s close:
DryShips Inc. (NASDAQ:DRYS)
DryShips Inc. (NASDAQ:DRYS) shares are down nearly 10% during the premarket, after it announced an agreement to amend its secured revolving facility with Sifnos Shareholders Inc to extend the facility’s maturity and make it unsecured. The Sifnos Facility will cease to be secured by DryShips’ present and future assets, and the maturity will be extended from three years to five years. Here’s a look at DRYS on the daily chart, as of yesterday’s close:
Maxwell Technologies Inc. (NASDAQ:MXWL)
Maxwell Technologies Inc. (NASDAQ:MXWL) shares are up nearly 20% ahead of the open, after it signed a $47M strategic equity investment agreement with China’s SDIC Fund Management. After the closing of the transaction, SDIC Fund Management’s ownership stake in Maxwell’s common stock is expected to represent nearly 20% of its total issued and outstanding shares of common stock. Here’s a look at MXWL, as of the close yesterday, on the daily chart:
It’s a slow day on the economic calendar, with just one major event: JOLTS number at 10:00 AM ET. The prior level of job openings was 5.626M.